⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DYN News
Dyne Therapeutics, Inc. Common Stock
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
globenewswire.com
DYN
It’s Time to Set Things Right at Dynacor and Ensure the Viability and Success of the Company
businesswire.com
DYN
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
DYN
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
globenewswire.com
DYN
Dyne Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
DYN
Form 8-K
sec.gov
DYN
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com
DYN
10th Capital Link Maritime Leaders Summit - A Posidonia Conference Program Event
globenewswire.com
TEN
CLPS
BVS
LILA
RS
DHT
DSS
LPG
DYN
ECO
FLO
GSL
SA
SN
ST
SM
CTM
TORO
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
globenewswire.com
DYN
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
DYN